Welcome to our dedicated page for Ironwood SEC filings (Ticker: IRWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ironwood Pharmaceuticals, Inc. filings document a Nasdaq-listed biotechnology company focused on gastrointestinal and rare disease therapies. Its Form 8-K reports include operating and financial results, business updates for LINZESS and apraglutide, regulatory and pricing matters involving LINZESS, and financing-related disclosures tied to credit agreements and liquidity conditions.
Proxy filings cover board elections, executive compensation votes, equity incentive plan matters, auditor ratification, and annual meeting procedures. Other filings address governance changes, Nasdaq listing-compliance matters for its Class A common stock, and the registered security structure of IRWD shares on the Nasdaq Global Select Market.
Ironwood Pharmaceuticals, Inc. reported that stockholders approved an amendment to its Amended and Restated 2019 Equity Incentive Plan at the 2026 Annual Meeting of Stockholders. The amendment increases the number of shares of Class A common stock available for issuance under the plan by 10,000,000 shares, expanding the pool for future equity-based compensation grants.
Stockholders also voted on the election of directors and other proposals, with each director nominee receiving over 104 million votes in favor and substantial broker non-votes recorded. Additional proposals received support levels including 104,461,936 votes for one item and 121,957,895 votes for another, indicating strong overall approval.
Shepard Jay reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC director Jay Shepard received a grant of 63,481 shares of Class A common stock as equity compensation. The restricted stock was granted at no cash cost to him under the Second Amended and Restated Non-employee Director Compensation Policy.
According to the grant terms, these restricted shares vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year. Following this award, Shepard directly holds a total of 235,036 shares of Ironwood Class A common stock.
Kessler Marla L reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC director Marla L. Kessler received a grant of 63,481 shares of Class A Common Stock as restricted stock. The award was granted under the company’s Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.
The restricted stock vests in full on the date immediately preceding the annual meeting of stockholders for the next calendar year. Following this grant, Kessler directly holds 229,364 shares of Class A Common Stock, reflecting routine equity-based director compensation rather than an open-market purchase or sale.
Currie Mark G reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC director Mark G. Currie received a grant of 63,481 shares of Class A common stock as restricted stock, awarded at no cash cost to him as part of director compensation.
According to the company’s non-employee director compensation policy, this restricted stock vests in full on the date immediately before the next year’s annual meeting of stockholders. After this award, Currie directly holds 676,900 shares of Ironwood common stock.
Duane Jon R reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC director Jon R. Duane received a grant of 63,481 shares of Class A Common Stock as equity compensation. The award was made at a price of $0.00 per share under the company’s Second Amended and Restated Non-employee Director Compensation Policy.
The restricted stock will vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year. Following this grant, Duane directly holds a total of 253,820 shares of Ironwood Pharmaceuticals common stock. This filing reflects a routine director equity award rather than an open-market purchase or sale.
Ironwood Pharmaceuticals director Alexander J. Denner reported stock awards of Class A Common Stock, received as non-cash compensation. On June 16, 2026, he acquired 63,481 shares at a price of $0.00 per share, increasing his direct holdings to 323,855 shares.
On June 15, 2026, he was also granted 4,065 shares at $0.00 per share, with 260,374 shares held directly after that grant. The footnotes state these restricted shares were issued under Ironwood’s Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, and will vest in full on the date immediately preceding the next year’s annual meeting of stockholders.
IRONWOOD PHARMACEUTICALS INC director Julie McHugh reported both a sale and a share grant of Class A Common Stock. She sold 21,571 shares at a weighted average price of $3.73 per share in open-market transactions executed under a pre-arranged Rule 10b5-1 trading plan. She also received a grant of 63,481 restricted shares at no cost under the company’s non-employee director compensation policy. These restricted shares vest in full on the date immediately preceding the next calendar year’s annual meeting of stockholders. After these transactions, she directly holds 272,320 shares.
Moukheibir Catherine reported acquisition or exercise transactions in this Form 4 filing.
Ironwood Pharmaceuticals director Catherine Moukheibir received an equity award of 63,481 shares of Class A common stock as compensation. The shares were granted at no cash cost to her and are structured as restricted stock under the company’s Second Amended and Restated Non-employee Director Compensation Policy.
These restricted shares will vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year, meaning she must remain in service through that date to receive them. After this grant, Moukheibir directly holds a total of 181,425 shares of Ironwood Class A common stock.
Ironwood Pharmaceuticals, Inc. reported that on June 15, 2026 it repaid in full the $200.0 million aggregate principal amount of its 1.50% convertible senior notes due 2026 at their scheduled maturity. The repayment was funded entirely from available cash on hand.
No noteholders elected to convert the 2026 convertible notes into equity, and the capped call transactions entered into in connection with the original issuance of these notes terminated upon expiry.